Mercure Pharmaceuticals (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 6.41 Cr
- Revenue Growth -6.42%
- Profit Growth 15.22%
- Ebitda 35.38%
- Net Worth 19.42%
- Total Assets -17.47%
About Mercure Pharmaceuticals (Opc)
Mercure Pharmaceuticals (Opc) Private Limited (MPOPL) is a Company incorporated in India on 01 August 2016 (Eight years and six months 25 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹6.41 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Siddhant Jain serves as a director at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290MP2016OPC041240
- Company No.
041240
- Incorporation Date
01 Aug 2016
- Date of AGM
02 Jul 2019
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Mercure Pharmaceuticals (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siddhant Jain  | Director | 01-Aug-2016 | Current |
Financial Performance of Mercure Pharmaceuticals (Opc).
Mercure Pharmaceuticals (Opc) Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.42% decrease. The company also saw a substantial improvement in profitability, with a 15.22% increase in profit. The company's net worth Soared by an impressive increase of 19.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mercure Pharmaceuticals (Opc)?
In 2023, Mercure Pharmaceuticals (Opc) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹64.10 M
Charges Breakdown by Lending Institutions
- Others : 3.21 Cr
- Hdfc Bank Limited : 3.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Feb 2021 | Hdfc Bank Limited | ₹3.20 Cr | Satisfied |
| 25 Jun 2020 | Others | ₹3.10 M | Satisfied |
| 13 Jun 2019 | Others | ₹2.90 Cr | Satisfied |
How Many Employees Work at Mercure Pharmaceuticals (Opc)?
Unlock and access historical data on people associated with Mercure Pharmaceuticals (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mercure Pharmaceuticals (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mercure Pharmaceuticals (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.